Literature DB >> 25503514

A decade of innovation in pharmaceutical R&D: the Chorus model.

Paul K Owens1, Eyas Raddad1, Jeffrey W Miller1, John R Stille1, Kenneth G Olovich1, Neil V Smith1, Rosie S Jones1, Joel C Scherer1.   

Abstract

Chorus is a small, operationally independent clinical development organization within Eli Lilly and Company that specializes in drug development from candidate selection to clinical proof of concept. The mission of Chorus is to achieve proof of concept rapidly and at a low cost while positioning successful projects for 'pharma-quality' late-stage development. Chorus uses a small internal staff of experienced drug developers and a network of external vendors to design and implement chemistry, manufacturing and control processes, preclinical toxicology and biology, and Phase I/II clinical trials. In the decade since it was established, Chorus has demonstrated substantial productivity improvements in both time and cost compared to traditional pharmaceutical research and development. Here, we describe its development philosophy, organizational structure, operational model and results to date.

Entities:  

Mesh:

Year:  2014        PMID: 25503514     DOI: 10.1038/nrd4497

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  22 in total

1.  An assessment of R&D productivity in the pharmaceutical industry.

Authors:  Nicola Dimitri
Journal:  Trends Pharmacol Sci       Date:  2011-10-24       Impact factor: 14.819

2.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

Authors:  Paul Morgan; Piet H Van Der Graaf; John Arrowsmith; Doug E Feltner; Kira S Drummond; Craig D Wegner; Steve D A Street
Journal:  Drug Discov Today       Date:  2011-12-29       Impact factor: 7.851

Review 3.  Diagnosing the decline in pharmaceutical R&D efficiency.

Authors:  Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

4.  Spending on new drug development1.

Authors:  Christopher Paul Adams; Van Vu Brantner
Journal:  Health Econ       Date:  2010-02       Impact factor: 3.046

5.  Rebuilding the R&D engine in big pharma.

Authors:  Jean-Pierre Garnier
Journal:  Harv Bus Rev       Date:  2008-05

6.  Does size matter in R&D productivity? If not, what does?

Authors:  Michael Ringel; Peter Tollman; Greg Hersch; Ulrik Schulze
Journal:  Nat Rev Drug Discov       Date:  2013-10-18       Impact factor: 84.694

7.  A more rational approach to new-product development.

Authors:  Eric Bonabeau; Neil Bodick; Robert W Armstrong
Journal:  Harv Bus Rev       Date:  2008-03

8.  Proof of concept: a PhRMA position paper with recommendations for best practice.

Authors:  M E Cartwright; S Cohen; J C Fleishaker; S Madani; J F McLeod; B Musser; S A Williams
Journal:  Clin Pharmacol Ther       Date:  2010-02-03       Impact factor: 6.875

Review 9.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Authors:  David Cook; Dearg Brown; Robert Alexander; Ruth March; Paul Morgan; Gemma Satterthwaite; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

10.  Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes.

Authors:  Joanne Sloan-Lancaster; Eyas Abu-Raddad; John Polzer; Jeffrey W Miller; Joel C Scherer; Andrea De Gaetano; Jolene K Berg; William H Landschulz
Journal:  Diabetes Care       Date:  2013-03-20       Impact factor: 19.112

View more
  18 in total

1.  Why is it hard to terminate failing projects in pharmaceutical R&D?

Authors:  Richard W Peck; Dennis W Lendrem; Iain Grant; B Clare Lendrem; John D Isaacs
Journal:  Nat Rev Drug Discov       Date:  2015-08-21       Impact factor: 84.694

Review 2.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 3.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

Review 4.  Has molecular imaging delivered to drug development?

Authors:  Philip S Murphy; Neel Patel; Timothy J McCarthy
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2017-11-28       Impact factor: 4.226

5.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

Review 6.  Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.

Authors:  Maria Angeles Martinez-Grau; Maria Alvim-Gaston
Journal:  Pharmaceut Med       Date:  2019-06

Review 7.  Genetics of human metabolism: an update.

Authors:  Gabi Kastenmüller; Johannes Raffler; Christian Gieger; Karsten Suhre
Journal:  Hum Mol Genet       Date:  2015-07-09       Impact factor: 6.150

8.  Sources of Information as Determinants of Product and Process Innovation.

Authors:  Jaime Gómez; Idana Salazar; Pilar Vargas
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240

Review 9.  Changing R&D models in research-based pharmaceutical companies.

Authors:  Alexander Schuhmacher; Oliver Gassmann; Markus Hinder
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

Review 10.  Value-Generating Exploratory Trials in Neurodegenerative Dementias.

Authors:  Lauren G Friedman; Nicholas McKeehan; Yuko Hara; Jeffrey L Cummings; Dawn C Matthews; Jian Zhu; Richard C Mohs; Deli Wang; Suzanne B Hendrix; Melanie Quintana; Lon S Schneider; Michael Grundman; Samuel P Dickson; Howard H Feldman; Judith Jaeger; Elizabeth C Finger; J Michael Ryan; Debra Niehoff; Susan L-J Dickinson; Jessica T Markowitz; Meriel Owen; Alessio Travaglia; Howard M Fillit
Journal:  Neurology       Date:  2021-03-05       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.